CFB and infection: Pretreatment of HAE cells with Cilgavimab/Tixagevimab significantly reduced Delta- (P < 0.0001) (Figure 2A) and BA.2-mediated infection (P = 0.024) (Figure 2C), while no effect was observed upon infection of bronchial epithelial cells with the BA.1 variant (Figure 2B and Supplementary Figure 2A).